(Q33542856)

27 July 2017

Lovastatin induces apoptosis of ovarian cancer cells and synergizes with doxorubicin: potential therapeutic relevance (English)

1 reference

27 July 2017

1 reference

1 reference

1 reference

Linda Z Penn

4

0 references

author name string

Anna Martirosyan

series ordinal

1

1 reference

27 July 2017

James W Clendening

series ordinal

2

1 reference

27 July 2017

Carolyn A Goard

series ordinal

3

1 reference

27 July 2017

language of work or name

English

0 references

publication date

18 March 2010

1 reference

27 July 2017

1 reference

27 July 2017

10

1 reference

27 July 2017

103

1 reference

https://scigraph.springernature.com/pub.10.1186/1471-2407-10-103

27 July 2017

0 references

cites work

Impact of statin therapy on survival in epithelial ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2847546

Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2847546

Lipophilic but not hydrophilic statins selectively induce cell death in gynaecological cancers expressing high levels of HMGCoA reductase

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2847546

Statins induce apoptosis in ovarian cancer cells through activation of JNK and enhancement of Bim expression

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2847546

Antineoplastic agents in the management of ovarian cancer: current status and emerging therapeutic strategies

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2847546

Lovastatin enhances the antitumoral and apoptotic activity of doxorubicin in murine tumor models.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2847546

Pharmaceutical management of ovarian cancer : current status

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2847546

21 June 2018

Cancer statistics, 2008

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2847546

Statins in tumor suppression

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2847546

CUL7 is a novel antiapoptotic oncogene

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2847546

Post-diagnosis statin use and breast cancer recurrence in a prospective cohort study of early stage breast cancer survivors

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2847546

Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2847546

Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + high-dose Ara-C: a phase 1 study

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2847546

Lovastatin protects human endothelial cells from the genotoxic and cytotoxic effects of the anticancer drugs doxorubicin and etoposide

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2847546

Anticancer drugs induce mdr1 gene expression in recurrent ovarian cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2847546

Breast cancer growth prevention by statins

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2847546

Dose-finding study of high-dose simvastatin combined with standard chemotherapy in patients with relapsed or refractory myeloma or lymphoma.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2847546

Actions of a histone deacetylase inhibitor NSC3852 (5-nitroso-8-quinolinol) link reactive oxygen species to cell differentiation and apoptosis in MCF-7 human mammary tumor cells

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2847546

Functional comparison of single- and double-stranded mdr1 antisense oligodeoxynucleotides in human ovarian cancer cell lines

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2847546

Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2847546

Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2847546

Flow cytometry-based approach to ABCG2 function suggests that the transporter differentially handles the influx and efflux of drugs

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2847546

Blocking the Raf/MEK/ERK pathway sensitizes acute myelogenous leukemia cells to lovastatin-induced apoptosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2847546

Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2847546

Ovarian cancer: strategies for overcoming resistance to chemotherapy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2847546

HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2847546

HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2847546

Lovastatin induces a pronounced differentiation response in acute myeloid leukemias

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2847546

Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2847546

HMG-CoA reductase inhibitors and P-glycoprotein modulation

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2847546

Differential sensitivity of various pediatric cancers and squamous cell carcinomas to lovastatin-induced apoptosis: therapeutic implications

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2847546

Effect of p53 status on sensitivity to platinum complexes in a human ovarian cancer cell line.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2847546

A phase I-II trial of lovastatin for anaplastic astrocytoma and glioblastoma multiforme

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2847546

Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2847546

Effects of lovastatin on a human myeloma cell line: increased sensitivity of a multidrug-resistant subline that expresses the 170 kDa P-glycoprotein.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2847546

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2847546

Regulation of the mevalonate pathway

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2847546

Determinants of sensitivity to lovastatin-induced apoptosis in multiple myeloma

21 June 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-10-103

Lovastatin induced control of blast cell growth in an elderly patient with acute myeloblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-10-103

The cholesterol lowering drug lovastatin induces cell death in myeloma plasma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-10-103

Increased sensitivity of multidrug-resistant myeloid leukemia cell lines to lovastatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-10-103

A Phase I trial of prolonged administration of lovastatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or of the cervix

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-10-103

High dose simvastatin does not reverse resistance to vincristine, adriamycin, and dexamethasone (VAD) in myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-10-103

ABCB1 (MDR 1) polymorphisms and progression-free survival among women with ovarian cancer following paclitaxel/carboplatin chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-10-103

Pretreatment with statin attenuates the cardiotoxicity of Doxorubicin in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-10-103

Phase II study of high-dose lovastatin in patients with advanced gastric adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-10-103

Pharmacodynamic effects of high dose lovastatin in subjects with advanced malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-10-103

Security and maximal tolerated doses of fluvastatin in pediatric cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-10-103

Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-10-103

Treatment of HCC with pravastatin, octreotide, or gemcitabine--a critical evaluation.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2847546

Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: A potential therapeutic approach

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2847546

Focus on epithelial ovarian cancer

31 October 2018

1 reference

12 December 2020

Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin

1 reference

12 December 2020

HMG-CoA reductase mediates the biological effects of retinoic acid on human neuroblastoma cells: lovastatin specifically targets P-glycoprotein-expressing cells

1 reference

12 December 2020

First clinical experience with simvastatin to overcome drug resistance in refractory multiple myeloma

1 reference

12 December 2020

Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition

1 reference

12 December 2020

Evaluation of methods to detect p53 mutations in ovarian cancer

1 reference

12 December 2020

Identifiers

DOI

10.1186/1471-2407-10-103

1 reference

Dimensions Publication ID

27 July 2017

0 references

1 reference

27 July 2017

1 reference